Wall Street analysts forecast that Maximus (MMS) will report quarterly earnings of $1.63 per share in its upcoming release, pointing to a year-over-year increase of 11.6%. It is anticipated that revenues will amount to $1.34 billion, exhibiting an increase of 1.7% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projecti ...

The upcoming report from Elastic (ESTC) is expected to reveal quarterly earnings of $0.58 per share, indicating a decline of 1.7% compared to the year-ago period. Analysts forecast revenues of $418.13 million, representing an increase of 14.4% year over year.Over the last 30 days, there has been a downward revision of 37.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course o ...

Core Insights - Akamai Technologies (AKAM) is expected to report quarterly earnings of $1.64 per share, a 3.1% increase year-over-year, with revenues projected at $1.04 billion, reflecting a 3.7% year-over-year growth [1] Earnings Projections - Analysts emphasize the importance of revisions to earnings projections prior to earnings releases, as these revisions are critical indicators of potential investor behavior [2] - The consensus EPS estimate for Akamai has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1] Revenue Estimates - Analysts predict 'Revenue- Security' will reach $569.75 million, showing a year-over-year increase of 9.9% [4] - 'Revenue- Compute' is expected to be $188.02 million, reflecting a 12.7% increase from the prior-year quarter [4] - 'Revenue- Delivery' is forecasted to be $285.18 million, indicating a decline of 10.6% from the prior-year quarter [4] Stock Performance - Akamai shares have returned -5% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change [5] - With a Zacks Rank 2 (Buy), Akamai is anticipated to outperform the overall market in the near future [5]

Core Insights - Analysts project that Brown & Brown (BRO) will report quarterly earnings of $0.90 per share, reflecting a year-over-year decline of 1.1%, while revenues are expected to reach $1.51 billion, marking a 27% increase from the same quarter last year [1] Earnings Projections - The consensus EPS estimate has been revised downward by 1.3% in the past 30 days, indicating a reassessment by covering analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Metrics - Analysts project 'Revenues- Investment income' to be $32.98 million, a 6.4% increase from the prior-year quarter [5] - 'Revenues- Commissions and fees' are expected to reach $1.47 billion, reflecting a 27.4% increase year-over-year [5] - The average prediction for 'Total revenues- Other' is $26.15 million, indicating a 24.5% year-over-year change [5] Stock Performance - Over the past month, shares of Brown & Brown have decreased by 4.2%, contrasting with the Zacks S&P 500 composite's increase of 1.1% [6] - Currently, BRO holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [6]

Core Insights - Analysts project Intel (INTC) will announce quarterly earnings of $0.00 per share, reflecting a 100% year-over-year increase, while revenues are expected to decline by 1.3% to $13.11 billion [1] - The consensus EPS estimate has been revised upward by 2.1% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2] - Earnings estimate revisions are critical for predicting investor behavior and have a strong correlation with short-term stock price performance [3] Revenue Estimates - The consensus estimate for 'Net Revenues- All other- Total' is $966.92 million, suggesting a year-over-year decline of 6.9% [4] - Analysts forecast 'Net Revenues- Total Intel Products Group- Client Computing Group' to reach $8.13 billion, indicating a year-over-year increase of 10.9% [5] - 'Net Revenues- Total Intel Products Group- Data Center and AI' is expected to reach $3.96 billion, reflecting an 18.4% increase from the previous year [5] - 'Net Revenues- Intel Foundry Services' is projected at $4.37 billion, suggesting a slight year-over-year increase of 0.4% [6] - The overall 'Net Revenues- Total Intel Products Group' is expected to be $12.10 billion, indicating a year-over-year decline of 0.8% [6] Stock Performance - Over the past month, Intel shares have increased by 25.1%, significantly outperforming the Zacks S&P 500 composite, which saw a 1.1% change [6] - Intel holds a Zacks Rank 3 (Hold), suggesting its performance is likely to align with the overall market in the near term [6]

Core Viewpoint - Thermo Fisher Scientific (TMO) is expected to report quarterly earnings of $5.50 per share, a 4.2% increase year-over-year, with revenues projected at $10.9 billion, reflecting a 2.8% year-over-year increase [1]. Earnings Estimates - The consensus EPS estimate has been revised down by 0.5% in the last 30 days, indicating a reassessment by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Forecasts - Analysts forecast 'Revenues- Laboratory Products and Biopharma Services' to reach $5.93 billion, a year-over-year increase of 3.2% [5]. - The estimate for 'Revenues- Specialty Diagnostics' is $1.16 billion, also reflecting a 3.2% year-over-year increase [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.47 billion, indicating a 3.6% year-over-year increase [5]. - 'Revenues- Analytical Instruments' are projected at $1.80 billion, showing a slight decline of 0.3% year-over-year [6]. Geographic Revenue Projections - North America revenues are expected to reach $5.74 billion, a 2.7% increase from the prior year [6]. - Asia-Pacific revenues are projected at $1.99 billion, reflecting a 3.6% year-over-year increase [6]. - Revenues from Europe are estimated to be $2.77 billion, indicating a 3.1% year-over-year increase [7]. - Revenues from other regions are expected to be $379.01 million, showing a decline of 4.5% year-over-year [7]. Stock Performance - Over the past month, Thermo Fisher shares have increased by 11.6%, outperforming the Zacks S&P 500 composite, which saw a 0.7% change [7]. - Based on its Zacks Rank 4 (Sell), TMO is expected to underperform the overall market in the upcoming period [7].

Core Viewpoint - Analysts forecast Boston Scientific (BSX) will report quarterly earnings of $0.71 per share, reflecting a year-over-year increase of 12.7%, with revenues expected to reach $4.97 billion, an 18% increase compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts project 'Net Sales- MedSurg- Worldwide' at $1.70 billion, a 15% increase year-over-year [5]. - 'Net Sales- Cardiovascular- Worldwide' is expected to reach $3.27 billion, indicating a 19.7% year-over-year change [5]. - 'Net Sales- Cardiovascular- Cardiology- Worldwide' is estimated at $2.57 billion, reflecting a 20.9% increase from the prior year [5]. - 'Net Sales- Cardiovascular- Peripheral Interventions- Worldwide' is projected to be $697.63 million, a 15.9% increase year-over-year [6]. - 'Geographic Revenue- Rest of the World' is expected to be $1.76 billion, indicating a 9.1% year-over-year change [6]. - 'Geographic Revenue- U.S.' is projected at $3.21 billion, reflecting a 23.8% increase from the previous year [7]. Additional Sales Projections - 'Net Sales- Cardiovascular- Peripheral Interventions- International' is expected to reach $304.52 million, a 6.9% increase year-over-year [7]. - 'Net Sales- MedSurg- Neuromodulation- United States' is projected at $218.50 million, indicating a 3.6% increase [8]. - 'Net Sales- MedSurg- Neuromodulation- International' is expected to be $62.26 million, reflecting a 9.2% year-over-year change [8]. - 'Net Sales- MedSurg- Endoscopy- United States' is projected at $447.24 million, a 7.3% increase from the prior year [8]. - 'Net Sales- MedSurg- Endoscopy- International' is expected to reach $280.01 million, indicating a 7.3% increase year-over-year [9]. - 'Net Sales- MedSurg- Urology- United States' is forecasted to be $518.55 million, reflecting a significant 36.8% year-over-year change [9]. Stock Performance - Boston Scientific shares have changed by -0.5% in the past month, compared to a +0.7% move of the Zacks S&P 500 composite, with a Zacks Rank 2 (Buy) indicating expected outperformance in the near future [10].

Core Insights - Analog Devices (ADI) is expected to report quarterly earnings of $1.93 per share, a 22.2% increase year-over-year, with revenues projected at $2.76 billion, reflecting a 19.2% increase compared to the same period last year [1] Revenue Estimates by End Market - Revenue from the Consumer end market is forecasted to reach $352.36 million, indicating an 11.3% increase from the prior-year quarter [4] - Revenue from the Communications end market is projected at $321.10 million, suggesting a 20.4% year-over-year change [4] - Revenue from the Automotive end market is likely to be $798.62 million, reflecting a 19.1% increase from the year-ago quarter [5] - Revenue from the Industrial end market is expected to reach $1.27 billion, indicating a 20.3% year-over-year change [5] Market Performance - Over the past month, shares of Analog Devices have returned -2%, while the Zacks S&P 500 composite has seen a +3.3% change [5] - Currently, ADI holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [5]

Core Viewpoint - Analysts expect Medtronic to report quarterly earnings of $1.23 per share, indicating no change from the previous year, with revenues projected at $8.37 billion, reflecting a 5.7% increase year-over-year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2] Revenue Projections - Analysts predict 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' at $728.31 million, a year-over-year increase of 2.2% [4] - 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' is expected to reach $631.16 million, reflecting a 2.5% increase [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is forecasted at $1.20 billion, indicating a 5% increase [5] - 'Net Sales- U.S. Revenue' is estimated at $4.26 billion, suggesting a 4.3% year-over-year change [6] - 'Net Sales- ROW- Cardiovascular' is projected to reach $1.71 billion, reflecting a 6.6% increase [8] Specific Segment Insights - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is expected to be $332.01 million, indicating a 6.4% increase [7] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is estimated at $326.25 million, reflecting a 3.9% increase [7] - 'Net Sales- ROW- Medical Surgical- Surgical & Endoscopy' is projected at $960.12 million, indicating a 4.9% increase [8] Market Performance - Over the past month, Medtronic shares have recorded returns of 3.5%, aligning with the Zacks S&P 500 composite's performance [9]

Core Viewpoint - Analysts project that Nice (NICE) will report quarterly earnings of $2.99 per share, reflecting a year-over-year increase of 13.3%, with revenues expected to reach $713.92 million, a 7.5% increase from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.2% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts expect 'Revenue by Business Model- Cloud' to be $539.96 million, indicating a year-over-year change of +12.1% [5]. - The estimated 'Revenue by Business Model- Services' is projected at $142.15 million, reflecting a year-over-year decline of -3.7% [5]. - 'Revenue by Business Model- Product' is anticipated to be $31.80 million, suggesting a year-over-year decrease of -9.4% [5]. Geographic Revenue Projections - 'Geographic Revenues- Americas' are expected to reach $603.87 million, showing a year-over-year increase of +7.5% [6]. - 'Geographic Revenues- Asia Pacific' is projected at $39.19 million, indicating a significant year-over-year increase of +18.7% [6]. - 'Geographic Revenues- EMEA' is estimated to be $72.11 million, reflecting a year-over-year change of +3% [6]. Stock Performance - Over the past month, shares of Nice have decreased by -4%, while the Zacks S&P 500 composite has increased by +2.7% [7]. - Nice currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].